EP
AMRX icon

Essential Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Essential Partners’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9K Sell
1,091
-2,136
-66% -$29.3K 0.01% 934
2026
Q1 		$40.1K Hold
3,227
– – 0.01% 659
2025
Q4 		$40.7K Buy
3,227
+14
+0.4% +$160 0.01% 663
2025
Q3 		$32.2K Buy
3,213
+502
+19% +$4.51K 0.01% 738
2025
Q2 		$21.9K Buy
+2,711
New +$20.4K 0.01% 651

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Essential Partners's AMRX Position: Q2 2026 in Review

Essential Partners reduced its Amneal Pharmaceuticals (AMRX) stake by 66% in Q2 2026, selling an estimated $29.3K and leaving 1,091 shares worth $18.9K. The position accounts for 0.01% of the portfolio, ranked #934.

Essential Partners first reported a position in AMRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $40.7K in Q4 2025. 308 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Essential Partners held 1,091 shares of Amneal Pharmaceuticals worth $18.9K as of Q2 2026.
  • Essential Partners sold 2,136 Amneal Pharmaceuticals shares in Q2 2026, an estimated $29.3K.
  • Amneal Pharmaceuticals made up 0.01% of Essential Partners's portfolio in Q2 2026, its #934 holding.
  • Essential Partners first reported a position in Amneal Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Amneal Pharmaceuticals position peaked at $40.7K in Q4 2025.
  • 308 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.